Luigi Francesco Iannone

Preliminary evidence of long‐term safety and effectiveness of anti‐ CGRP drugs for migraine prevention in people with comorbid epilepsy: A 52‐week follow‐up retrospective study

Abstract Migraine and epilepsy frequently coexist, but evidence on the safety of calcitonin gene‐related peptide (CGRP)‐targeting therapies in people with epilepsy is lacking. We evaluated long‐term migraine and epilepsy outcomes in a real‐world multicenter retrospective cohort o...

Costs and use of antimigraine drugs in Italy: a ten-year analysis of national data

Abstract Background Migraine is a highly prevalent neurological disorder associated with substantial disability and economic burden. Considering the recent introduction of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs), expenditure analysis are needed to...